Evogene Ltd. — Investor Presentation 2023

Aug 8, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2023

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 Ag Plenus Investor Presentation.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: August 8, 2023 By: /s/ Yaron Eldad

Yaron Eldad Chief Financial Officer

Company Presentation

August 2023

Forward-Looking Statements

This presentation contains "forward-looking statements" relating to future events, and AgPlenus (the "Company") and its parent, Evogene Ltd. ("Evogene", and collectively "we", "us", "our"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, growing market's expectations, challenges, business model and potential revenue stream, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

Agenda

01// Vision, challenges & our solution

3

// 02 The technology platform

// 03 Product pipeline

// 04 Business development

// 05 Summary

Our Vision

Novel and safe crop protection products

Design and develop novel and safe crop protection products allowing food security for the rapidly growing world population

Our Mission

AI and science to boost novel crop protection development

To direct and accelerate the development of target-based novel crop protection products, utilizing a revolutionary tech-engine based on AI, combined with a deep understanding of biology and chemistry

Agrochemical Market Growth Drivers Market growth forecast for 2028 ~\$92B

2023 Est., ~\$70B (E.CAGR 4.7%)*

10B

The world's population in 2050

of the world's population lives in urban areas

60% **

increase in food production to feed the world

Agro-chemical pesticide

is a well proven economical approach for increase of crop yields

Agrochemical Market Challenges

Increase of Pest Resistance & Regulatory Requirements

• • Reduced tools due to regulatory requirements
• Resistant pests
• • Increased application rate resulting in environmental damage

Long and Expensive Development

• • Time to market 10-12 years
• • Average cost of \$286M
• 160K molecules synthesized

Lack of Innovation

• Decrease in discovery of new pesticides
• Lack of capabilities to identify protein targets

Novel products & an effective product development approach are urgently needed

Key Product Development Challenges

Target Protein - an essential protein, that upon loss of its function compromises the organism.

The Challenge

To find a novel, safe, and druggable Target Protein from the thousands of proteins in the relevant organism, with a new mode-of-action (MOA) that will not result in adverse crossreactivity in beneficial species.

02 Small Molecule Inhibitor Identification

A small molecule inhibitor - is a chemical compound that effectively modulates or inhibits the activity of the target protein.

The Challenge

To find a novel molecule inhibitor out of the billions of potential chemical compounds, that both effectively and selectively affects the target protein.

Our Solution - AI and Science for Novel Crop Protection

Computational prediction of essential druggable proteins

AI- based rapid virtual screening of 1010 compounds

Addressing environmental safety and selectivity early in discovery

Cost-effective, wet screening of only hundreds of compounds

Reduced time to market

Increase probability of success

Well-proven drug design in-silico approach assimilated into the tech-engine

Robust computational platform

AgPlenus' Holistic Discovery Approach

AgPlenus' Holistic Discovery Approach

TargetSelector -

A computational approach for identification of essential proteins

Cost-effective and time-efficient approach

Addressing environmental safety and selectivity early in discovery

Variety of novel targets (less researched)

TargetSelector

Essentiality

Druggability

Target Validation

Knocking down the targeted protein results in severe growth inhibition

No treatment (control)

In the presence of target gene silencer inducer

AgPlenus' Holistic Discovery Approach

PointHit - a Virtual High Throughput Screening Tool

• • Highly efficient deep docking of up to 30B compound DB (>400-fold acceleration)*
• • Supplemented with proprietary machinelearning (ML) tools to evaluate bioavailability

Advantages

Increases structural variability and ~100K opportunity to find Hits

Reduces the volume of downstream ~10K analysis - cost and time-effective Eyeballing

PointHit - Start-to-End Case Study

AgPlenus' Holistic Discovery Approach

ActiveSearch - Optimization Tool

A proprietary computational SAR tool to streamline Hit and Lead optimization process

ActiveSearch - Case Study

ActiveSearch Yielded Purchasable Active Compounds

Criterion	Pass/Fail	Comments
Compound availability	Pass	~95% purchasable
Compound activity	Pass	57% above the threshold (40% inhibition) 20% above 90% inhibition
Diversity	Pass	NEW chemicals identified

Additional Capabilities Under Development

Target discovery & prioritization

TargetSelector V.2.0

Automate target assessment process to increase speed and predictive success for the selection of commercially relevant novel protein targets

Hit discovery PointHit V.2.0

Predictive models for Ag activity to increase probability of success

Hit & Lead optimization

ActiveSearch V.1.1

Improved functionality, addition of features used in analog selection leading to enhanced predictive results

Hit & Lead optimization

De-Novo Design V.1.0

Design of novel compounds and assessment of synthetic feasibility resulting in fine tuning of products to better serve the target market while minimizing cost of goods

De-novo Design Addressing Lead-to-Candidate challenges

De-novo design of new chemical entities:

• Structure activity relationship analysis (SAR)
• Synthesis models computational assessment of ease of synthesis and route of synthesis

Dashboard User-Enabled Software

Chem H Pass V						agPlenus Cooperave
	Workflows
	DISCOVERY OPTIMIZATION
E	Discovery
国 国 国	01 Preparations -	Screening -	03 Structure - Based Analysis ----	04 Ligand - Based Analysis	05 Ranking & Filtering & Filtering	D6 Purchasing Support
	(3) Pharmacophore	( PointHit	Protein - Ligand Interactions Analysis @	(@) Toxicity Models	Pareto Calculation	Compound
	PointHit Configuration	(DeepDock	Detect interactions of interest for compounds prioritization	(a) Ag Models	Clustering
		(B) PointHit Report	@ Protein - Ligand	(4) Known
Apps		Download SDF
Powered by		Last Update Feb 2022 16B
evigene				New active search
					The new application actively searches Evogene's huge 2018 detabase and allows customized focus on similar compounds fo your leading compound at any stage of the lead optimiz
		M688
		25Өм
	75M 37M			TAKE ME THERE
	696K
	SAVI CHEMUNITY 1+2	Moule CHEMUNITY 3+4 Enamine REAL 5 Enamine REAL M

Our Products

Broad Spectrum Herbicide

Market opportunity

• Total herbicide estimated at \$30.3B¹
• Resistance to current top products

Major markets

- North America, Latin America

1) https://www.mordorintelligence.com/industry-reports/global-herbicides-market-industry?gclid=EAIaIQobChMIqL--hsHMgAMVoJODBx2ZLQeZEAAYAiAAEgLXqvD_BwE 2) https://www.mordorintelligence.com/industry-reports/global-insecticides-market-industry?gclid=EAIaIQobChMIwcXxqcHMgAMVkpCDBx2xiAeyEAAYASAAEgK5mfD_BwE 3) https://www.mordorintelligence.com/industry-reports/global-fungicides-market-industry

Piercing/Sucking Insecticide

Market opportunity

• Total insecticide market estimated at \$18.7B²
• Europe ban on insecticide classes

Major markets

• Global

Wheat Blotch Fungicide

Market opportunity

• Total fungicide market estimated at \$20.8³

• Resistance to current top products ('Strobilurins')

• Europe, Asia

• Needs in all major global regions

AgPlenus Pipeline

	Product Program Name / Type	Protein Name
			Protein Identification & Selection	Hit Identification	Hit & Lead Optimization	Pre Development
	HERBICIDES
	Broad spectrum	APTH 1		S1
				S2
				S3
	Corteva Collaboration		Confidential	Confidential
	INSECTICIDES
	Piercing/sucking	APTI 1		S1
	FUNGICIDES
	Wheat blotch
	S- scaffold
	Completed In process	Completed	In process In process

Business Model

Licensing Model

• • Development up to Lead optimization, by AgPlenus
• • Hand off to partner
• • Revenue via license, milestones, royalties

Collaboration Model

• • Co-development utilizing AgPlenus' and partner's capabilities
• • Flexible entry point along development path
• • Revenue via upfront fee, R&D reimbursement, milestones, royalties

Joint Product Model

• • Co-development starting at identification of market target
• • Revenue via R&D reimbursement, milestones, royalties

Go to Market Strategy

Collaboration Agreement

Develop new MoA herbicides to target resistant weeds

• • Started in March 2020
• • AgPlenus to discover & optimize herbicide candidates
• • Corteva to conduct testing & product development

License to Corteva

• • Corteva has exclusive license to products of collaboration
• • AgPlenus receives research fees, milestones & royalties upon commercialization

Partnership Opportunities

Full R&D capabilities companies

Interest in partnering for earlier innovation

Opportunities New projects, identified

targets, SAR, pipeline projects

Opportunities Pipeline projects

Generic companies

Asian entities

Opportunities Pipeline projects

Discovery companies

MoA

Opportunities

Target identification, hit ID, optimization

The Management Team

Innovative & Experienced Management Team

Brian Ember, PhD | CEO

Previous positions:

• • Biotalys, Head of Global Portfolio Management & Head of Marketing
• AgriMetis, Business Development

Yaron Elad | CFO

Previous positions:

• • Yamba Group Int. Ltd, CFO
• • Recoly NV, CFO
• • e-Sim Ltd., CFO

Merav Beiman, PhD | VP R&D

Previous positions:

• ImmPACT-Bio, CEO
• Ferring, R&D
• Compugen, R&D
• QBI, R&D

Mirit Ram, MSc | VP Portfolio Management

Previous positions:

• Evogene, PM
• FMC, PM
• HP, R&D

Liat Foigel-Wejgman | VP HR

Previous positions:

• Evogene, HR Director

Board

Experienced Board of Directors

Ofer Haviv | Chairman of The Board

• Evogene, President & CEO

Eran Kosover | Director

• Atera Networks
• Previously: AgPlenus Ltd., CEO
• Previously: Evogene, EVP & GM Crop Protection

Adrian Percy | Director

• North Carolina Plant Sciences Initiative (N.C. PSI), Executive Director
• Board of Directors: Evogene, BioLumic, Nufarm, FA Bio
• Previously: UPL, CTO
• Previously: Head of R&D, Bayer

Robert A. Woods | Director

• Former Chair of Marrone Bio Innovations,
• CEO and Chair of Targeted Growth Inc.
• Former Chair of Syngenta Corp, US

Sassi Masliah | Director

• Evogene, VP Corporate Development

Summary

Target-based design with new MoA for sustainable and resistance breaking products Target-based design with new MoA for sustainable and resistance breaking products

Combined computational and biological platforms

31

31

Continuous incremental tech platform improvements Continuous incremental tech platform improvements

Higher probability of success

Large molecule Large molecule database provides wide chemical space

Flexible business model

THANK YOU

www.agplenus.com